<p>Ascentage Pharma Group International has presented updated clinical data on Olverembatinib, its novel therapy for second-line treatment of chronic myeloid leukemia in chronic-phase (CML-CP), at the 67th American Society of Hematology (ASH) Annual Meeting. The results showed a 76.7% complete cytogenetic response rate in patients who had failed first-line therapy with second-generation tyrosine kinase inhibitors (TKIs). Molecular responses deepened with extended treatment duration, with a major molecular response rate reaching 60% at 21 cycles. The company reported that the efficacy data support the potential for advancing Olverembatinib to earlier lines of treatment for a broader patient population. The findings presented were updates from results previously released at ASH 2024 and included longer follow-up data on efficacy and safety. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-119453), on December 09, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

AAPG

06855

<p>Ascentage Pharma presented promising clinical data on Olverembatinib for second-line CML treatment at ASH 2025, showing a 76.7% complete cytogenetic response rate and a 60% major molecular response rate at 21 cycles. The data supports advancing Olverembatinib to earlier treatment lines. The findings update previous ASH 2024 results with longer follow-up data.</p>

Ascentage Pharma Reports Promising Second-Line CML Results for Olverembatinib at ASH 2025